Compare Incyte Corporation (INCY) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Keysight Technologies Inc — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.99B), while Keysight Technologies Inc trades at $380.3 (market cap $64.93B). The key difference: Keysight Technologies Inc is far larger — about 2.8× Incyte Corporation's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Keysight Technologies Inc for 56 Days on average.
| INCY | KEYS | |
|---|---|---|
Market Cap | $22.99B | $64.93B |
Volume | 1,274,487 | 1,037,588 |
Sector | Health | Technology |
52-Week High | $129.93 | $387.90 |
52-Week Low | $83.80 | $159.49 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $18.50B | $65.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $112.75, up 0.02% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported strong Q2 2026 earnings, beating expectations with EPS of $3.09 versus $2.15, and revenue growth from $5.14B in 2025 to a projected $5.8B in 2026. Recent FDA approval for Atebrioz and a strategic push for post-JAKAFI growth highlight pipeline progress. Valuation ratios appear reasonable with a P/E of 14.45 and EV/EBITDA of 8.94.
Outlook is positive with a consensus price target of $132.07, implying 17% upside, supported by 52% analyst buy ratings. Risks include reliance on JAKAFI, which loses exclusivity after 2029, and near-term earnings volatility as seen in the Q4 2025 miss. Strong cash flow and profitability metrics suggest resilience, but execution on pipeline diversification is critical for sustained growth.
Keysight Technologies (KEYS) trades at $374.66, down 3.41% on the day but remains in a bullish technical trend with strong analyst support. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.07 surpassing the $2.48 estimate. Revenue for 2025 reached $5.38 billion, with a net income margin of 15.81%. Recent news highlights growth in AI infrastructure and 6G testing solutions.
Outlook is positive driven by AI and 6G demand, but high valuation multiples pose a risk. The consensus price target of $416.63 implies 11% upside. Key risks include supply constraints and competitive pressures in the semiconductor testing space. Institutional sentiment remains bullish with 81% of analysts rating the stock a buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
